ARMI | BioFabUSA recently caught up with Marsha Rolle, associate professor of Biomedical Engineering at WPI, to discuss WPI’s membership and observations about regenerative medicine.
John Hartner, CEO of Dimension Inx, sees smoother regulatory pathways as essential to the near term availability of surgically friendly tissue for grafts.
“Collaboration is going to be the key factor for this new industry in biofabrication,” said Eric Gatenholm, co-founder and CEO of CELLINK, which quickly rose to IPO in under one year.
“Histogenics is a microcosm of ARMI/BioFabUSA in the regenerative medicine area of cartilage and musculoskeletal tissues,” said Steve Kennedy, Chief Operating Officer. “Our platform includes the process, manufacturing, regulatory, QC and clinical supplies for our industry,” he continued.
Michael Golway, CEO of Kentucky-based Advanced Solutions, is so committed to the mission of someday manufacturing human organs that he is moving dozens of staff from Kentucky to New Hampshire by the end of the 1st quarter in 2018.